Skip to content

Author

Paola Guglielmelli

We have 3 of 43 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Characterization of FLT3-ITD-mutated leukemic stem cells: functional and clinical insights

Despite treatment advances, relapsed/refractory FLT3 -ITD-mutated acute myeloid leukemia ( FLT3 -ITD mut AML) remains an unmet medical need. We previously identified a CD34/CD123/CD25/CD99+ leukemic progenitor cell (LPC) population that persists after induction treatment and drives disease recurrence in FLT3...

S. Travaglini, T. Ottone, S. Antonelli et al. · 0 citations
Open access Sep 2026

Healthcare Utilization Databases for Real-World Outcome Analysis of Ruxolitinib Treatment in Myelofibrosis

Introduction Myelofibrosis (MF) is a BRC::ABL1-negative myeloproliferative neoplasm characterised by a heterogeneous clinical phenotype encompassing abnormalities in blood counts, bone marrow fibrosis, splenomegaly, constitutional symptoms and vascular complications. MF may progress to accelerated phase (AP) and blast...

Barbara Mora, M. Franchi, L. Margotto et al. · 0 citations
Open access Sep 2026

iMTSS: an integrated framework for biology- and patient-driven prognosis in myelofibrosis undergoing transplantation.

Relapse and non-relapse mortality after transplantation for myelofibrosis are governed by distinct dimensions, and estimating both outcomes independently with genetic and clinical information, in addition to overall survival, establishes an individualized basis for transplant decision-making.

N. Gagelmann, R. Salit, T. Schroeder et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.